Caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the global pandemic of the coronavirus disease of 2019 (COVID-19) had resulted in over 1 million cases and 50 thousand deaths in the United Kingdom, and over 50 million reported cases and over 1.2 million deaths worldwide. (Data as of 10-November-2020) While there are now hundreds of vaccine trials globally, checks on their safety will be paramount, and monitoring of side effects will be necessary. The ability to identify and understand the background rates of Adverse Events of Special Interests (AESI) for COVID-19 vaccines is critical for future vaccine safety surveillance.
Meanwhile, although some studies had been done in the background rates, the algorithms of identifying the outcomes in electronic health records, especially in Clinical Practice Research Datalink (CPRD), varies between studies. Even if there are commonly used clinical case definition, the interpretation from clinical description to database algorithms could be different as well. In this study, we aim to identify and evaluate selected AESI in the electronic health records data from General Practice and hospitals, and to estimate the incidence rates of AESI in the UK population, and after viral infections like influenza and COVID-19.
This study will inform the identification of AESI in CPRD, and provide key information on the disease characteristics of AESI in the general UK population. This information will help future safety studies of COVID-19 vaccines when available.
The global pandemic of COVID-19 has resulted in over 50 million reported cases and over 1.2 million deaths globally. Meanwhile, hundreds of vaccines are in clinical evaluation and some show clinical efficacy. While planning for the large-scale immunization program, it is important to understand the potential adverse events after vaccination or viral infections. Electronic health records, including CPRD, have been increasingly used in safety studies. The ability to and the reliability of capturing the adverse events using suitable phenotyping algorithms in such databases are the foundation in conducting these studies. We will firstly identify the phenotyping algorithms of the AESI used in other studies, or develop the phenotypes if no existing one is found. Then we will evaluate the performance of these phenotypes using the diagnostic and evaluation tool that had been previously developed. The second objective is to estimate the background incidence rates (IR) of the AESI among the general population from the year 2006 to 2019. Individuals who were observed for at least 365 days during the study period will be included. The numerator of the incidence rate will be the total number of incident cases in each year, and the denominator will be person-time at risk each year. We will also estimate the IR among patients who were diagnosed or received a positive test for COVID-19 (after 31-Jan-2020) or seasonal influenza. We will apply different algorithms in identifying both the exposures and the outcomes. A tested negative cohort will be identified using primary care data as a negative control group as well. We will then carry on a self-controlled case series analysis to exam the association between developing the AESI and COVID-19 or influenza infections using the conditional Poisson regression model. A set of sensitivity analyses will be conducted to test the assumptions of this method.
Health Outcomes to be Measured:
1.Neurologic/ neuropsychiatric (Guillain Barré Syndrome (GBS), Miller Fisher syndrome, Encephalomyelitis (include Acute disseminated encephalomyelitis (ADEM)), Meningitis, Encephalitis, Aseptic meningitis, Encephalitis / Encephalomyelitis, Meningoencephalitis, Anosmia, ageusia, Generalized convulsion, Transverse myelitis, Narcolepsy, Bell’s palsy, Other Cranial nerve disorders (other than VII)); 2.Immunologic (Acute aseptic arthritis, Anaphylaxis, Vasculitis, Arthritis, Type I Diabetes); 3. Hematologic (Thrombocytopenia, Idiopathic thrombocytopenic purpura (ITP), Coagulation disorder: Deep vein thrombosis , Pulmonary embolus , Cerebrovascular stroke, Limb ischemia, Hemorrhagic disease); 4.Cardiovascular system (Acute cardiac injury :Microangiopathy, Heart failure and cardiogenic shock, Stress cardiomyopathy, Coronary artery disease, Arrhythmia, Myocarditis, pericarditis, Ischemic stroke, intracerebral haemorrhage, CNS vasculitis (ANCA-associated vasculitis, Takayasu Arteritis and Giant Cell Arteritis)); 5.Respiratory system (Acute respiratory distress syndrome, spontaneous pneumothorax); 6.Dermatologic (Single organ cutaneous vasculitis, Erythema multiforme, Chilblain-like lesions); and 7.Others (Rhabdomyolysis).
HES Admitted;ONS;Patient IMD